FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145647613> ?p ?o ?g. }

• W2145647613 endingPage "1721" @default.
• W2145647613 startingPage "1712" @default.
• W2145647613 abstract "Epstein-Barr virus (EBV) has been associated with multiple sclerosis (MS), however, most studies examining the relationship between the virus and the disease have been based on serologies, and if EBV is linked to MS, CD8+ T cells are likely to be involved as they are important both in MS pathogenesis and in controlling viruses. We hypothesized that valuable information on the link between MS and EBV would be ascertained from the study of frequency and activation levels of EBV-specific CD8+ T cells in different categories of MS patients and control subjects. We investigated EBV-specific cellular immune responses using proliferation and enzyme linked immunospot assays, and humoral immune responses by analysis of anti-EBV antibodies, in a cohort of 164 subjects, including 108 patients with different stages of MS, 35 with other neurological diseases and 21 healthy control subjects. Additionally, the cohort were all tested against cytomegalovirus (CMV), another neurotropic herpes virus not convincingly associated with MS, nor thought to be deleterious to the disease. We corrected all data for age using linear regression analysis over the total cohorts of EBV- and CMV-infected subjects. In the whole cohort, the rate of EBV and CMV infections were 99% and 51%, respectively. The frequency of IFN-γ secreting EBV-specific CD8+ T cells in patients with clinically isolated syndrome (CIS) was significantly higher than that found in patients with relapsing–remitting MS (RR-MS), secondary-progressive MS, primary-progressive MS, patients with other neurological diseases and healthy controls. The shorter the interval between MS onset and our assays, the more intense was the EBV-specific CD8+ T-cell response. Confirming the above results, we found that EBV-specific CD8+ T-cell responses decreased in 12/13 patients with CIS followed prospectively for 1.0 ± 0.2 years. In contrast, there was no difference between categories for EBV-specific CD4+ T cell, or for CMV-specific CD4+ and CD8+ T-cell responses. Anti-EBV-encoded nuclear antigen-1 (EBNA-1)-specific antibodies correlated with EBV-specific CD8+ T cells in patients with CIS and RR-MS. However, whereas EBV-specific CD8+ T cells were increased the most in early MS, EBNA-1-specific antibodies were increased in early as well as in progressive forms of MS. Our data show high levels of CD8+ T-cell activation against EBV—but not CMV—early in the course of MS, which support the hypothesis that EBV might be associated with the onset of this disease." @default.
• W2145647613 created "2016-06-24" @default.
• W2145647613 creator A5001307100 @default.
• W2145647613 creator A5007165900 @default.
• W2145647613 creator A5019268525 @default.
• W2145647613 creator A5019435073 @default.
• W2145647613 creator A5031999147 @default.
• W2145647613 creator A5037162535 @default.
• W2145647613 creator A5070586980 @default.
• W2145647613 creator A5075371427 @default.
• W2145647613 creator A5085058399 @default.
• W2145647613 creator A5086195508 @default.
• W2145647613 date "2008-06-11" @default.
• W2145647613 modified "2023-10-13" @default.
• W2145647613 title "Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis" @default.
• W2145647613 cites W1964179737 @default.
• W2145647613 cites W1970726284 @default.
• W2145647613 cites W1979461324 @default.
• W2145647613 cites W1984168657 @default.
• W2145647613 cites W1990062483 @default.
• W2145647613 cites W1993741037 @default.
• W2145647613 cites W1996573297 @default.
• W2145647613 cites W1997379610 @default.
• W2145647613 cites W1997452632 @default.
• W2145647613 cites W1997910013 @default.
• W2145647613 cites W2004378054 @default.
• W2145647613 cites W2007366725 @default.
• W2145647613 cites W2012132621 @default.
• W2145647613 cites W2014068804 @default.
• W2145647613 cites W2014114920 @default.
• W2145647613 cites W2015125514 @default.
• W2145647613 cites W2016638413 @default.
• W2145647613 cites W2016917436 @default.
• W2145647613 cites W2019009797 @default.
• W2145647613 cites W2048303046 @default.
• W2145647613 cites W2050186788 @default.
• W2145647613 cites W2078229430 @default.
• W2145647613 cites W2078699094 @default.
• W2145647613 cites W2081632246 @default.
• W2145647613 cites W2083485745 @default.
• W2145647613 cites W2097266906 @default.
• W2145647613 cites W2105490558 @default.
• W2145647613 cites W2111480581 @default.
• W2145647613 cites W2114299067 @default.
• W2145647613 cites W2115364134 @default.
• W2145647613 cites W2118966296 @default.
• W2145647613 cites W2119301665 @default.
• W2145647613 cites W2122894564 @default.
• W2145647613 cites W2123097534 @default.
• W2145647613 cites W2133377947 @default.
• W2145647613 cites W2134290014 @default.
• W2145647613 cites W2135513801 @default.
• W2145647613 cites W2139016479 @default.
• W2145647613 cites W2139113477 @default.
• W2145647613 cites W2139988928 @default.
• W2145647613 cites W2145992817 @default.
• W2145647613 cites W2165944571 @default.
• W2145647613 cites W2916040650 @default.
• W2145647613 cites W4233694737 @default.
• W2145647613 cites W4250145052 @default.
• W2145647613 doi "https://doi.org/10.1093/brain/awn108" @default.
• W2145647613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18550621" @default.
• W2145647613 hasPublicationYear "2008" @default.
• W2145647613 type Work @default.
• W2145647613 sameAs 2145647613 @default.
• W2145647613 citedByCount "140" @default.
• W2145647613 countsByYear W21456476132012 @default.
• W2145647613 countsByYear W21456476132013 @default.
• W2145647613 countsByYear W21456476132014 @default.
• W2145647613 countsByYear W21456476132015 @default.
• W2145647613 countsByYear W21456476132016 @default.
• W2145647613 countsByYear W21456476132017 @default.
• W2145647613 countsByYear W21456476132018 @default.
• W2145647613 countsByYear W21456476132019 @default.
• W2145647613 countsByYear W21456476132020 @default.
• W2145647613 countsByYear W21456476132021 @default.
• W2145647613 countsByYear W21456476132022 @default.
• W2145647613 countsByYear W21456476132023 @default.
• W2145647613 crossrefType "journal-article" @default.
• W2145647613 hasAuthorship W2145647613A5001307100 @default.
• W2145647613 hasAuthorship W2145647613A5007165900 @default.
• W2145647613 hasAuthorship W2145647613A5019268525 @default.
• W2145647613 hasAuthorship W2145647613A5019435073 @default.
• W2145647613 hasAuthorship W2145647613A5031999147 @default.
• W2145647613 hasAuthorship W2145647613A5037162535 @default.
• W2145647613 hasAuthorship W2145647613A5070586980 @default.
• W2145647613 hasAuthorship W2145647613A5075371427 @default.
• W2145647613 hasAuthorship W2145647613A5085058399 @default.
• W2145647613 hasAuthorship W2145647613A5086195508 @default.
• W2145647613 hasBestOaLocation W21456476131 @default.
• W2145647613 hasConcept C126322002 @default.
• W2145647613 hasConcept C159047783 @default.
• W2145647613 hasConcept C159654299 @default.
• W2145647613 hasConcept C167672396 @default.
• W2145647613 hasConcept C203014093 @default.
• W2145647613 hasConcept C2522874641 @default.
• W2145647613 hasConcept C2776409557 @default.
• W2145647613 hasConcept C2777732132 @default.

• next